This drug provides a compound with pdhk inhibitory activity, which can be used to treat or prevent diabetes (type 1 diabetes mellitus, type 2 diabetes mellitus, etc.).Insulin resistance syndrome, metabolic syndrome, hyperglycemia, hyperlactose, diabetic complications (diabetic neuropathy, diabetic retinopathy, diabetic nephropathy, cataract, etc.)Heart failure (acute heart failure, chronic heart failure)Heart disease, near muscle ischemia, myocardial infarction, chest colic, degreasing disease, myocardial infarction, peripheral artery disease, intermittent desulfurization, chronic obstructive pulmonary disease, cerebral ischemia, stroke, mitochondrial disease, mitochondrial encephalopathy, cancer Pulmonary hypertension or Alzheimer's disease This table refers to a compound of formula [1] or formula [2], or a pharmaceutically acceptable salt, each of which has the same meaning as described in descriptive memory. Claim 1: a compound of formula [1] or formula [2], or a pharmaceutically acceptable salt thereof,a. The characteristic of point line linkage is single bond or double bond； X1 is carbon atom, nitrogen atom or oxygen atom； X2 is carbon atom or nitrogen atom； RS 749191 is c83183318324 matrix or c83318318324 matrix； carbonilo； R2 is halogen, cyanogen or tar, c832183318331831832483；M is 0 or 1； n is 0, 1 or 2, n is 2, which is the same or different per square kilometer； A1,……A3，A8308；A83099，A8310 and a8311 are independently selected from carbon, nitrogen and oxygen atoms； a831222 is selected from carbon and nitrogen atoms, and the total number of nitrogen and oxygen atoms contained in some structural formulas is 0, 1, 2 or 3； t is 0 or 1； R is 0, a. 1 or 2, the total amount of T and R is 1 or 2； W is 0 or 1； R3 and r83088 are independent hydrogen or c83218314838, respectively；CY1 ES（1）（I）cyclo C8322431；O (II) saturated or partially saturated isocyclohexane consisting of 4-6 members, having nitrogen atoms, cyclohexane c834248c83226 and saturated or partially satura
